We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

63 hedge funds and large institutions have $50.2M invested in Outlook Therapeutics in 2021 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 14

66% more capital invested

Capital invested by funds: $30.3M → $50.2M (+$19.9M)

29% more funds holding

Funds holding: 49 → 63 (+14)

0.19% more ownership

Funds ownership: 0.39% → 0.58% (+0.19%)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

Holders
63
Holders Change
+14
Holders Change %
+28.57%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
11
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.3M
2
State Street
State Street
Massachusetts
+$3.11M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.8M
4
Northern Trust
Northern Trust
Illinois
+$1.64M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.09M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.87M
2
Two Sigma Investments
Two Sigma Investments
New York
-$820K
3
Millennium Management
Millennium Management
New York
-$450K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$373K
5
ECM
ExodusPoint Capital Management
New York
-$319K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$13K -$4.13K -89 -26%
Citigroup
52
Citigroup
New York
$10K +$9.65K +208 New
APA
53
American Portfolios Advisors
New York
$9.96K +$9.28K +200 New
BNP Paribas Financial Markets
54
BNP Paribas Financial Markets
France
$8.4K +$7.84K +169 New
JCM
55
Jacobi Capital Management
Pennsylvania
$7K – – –
TRCT
56
Tower Research Capital (TRC)
New York
$4K -$52.4K -1,129 -93%
CFGS
57
Concourse Financial Group Securities
Alabama
$3K – – –
HI
58
Harbour Investments
Wisconsin
$3K – – –
PWMG
59
Prestige Wealth Management Group
New Jersey
$3K – – –
AIG
60
American International Group
New York
$122 +$114K +2,454 New
Walleye Capital
61
Walleye Capital
New York
$72 +$67.3K +1,450 New
Renaissance Technologies
62
Renaissance Technologies
New York
– -$1.87M -41,628 Closed
Millennium Management
63
Millennium Management
New York
– -$450K -10,001 Closed
Susquehanna International Group
64
Susquehanna International Group
Pennsylvania
– -$373K -8,292 Closed
ECM
65
ExodusPoint Capital Management
New York
– -$319K -7,095 Closed
Marshall Wace
66
Marshall Wace
United Kingdom
– -$182K -4,041 Closed
LP
67
LMR Partners
United Kingdom
– -$124K -2,749 Closed
HF
68
HRT Financial
New York
– -$64K -1,434 Closed
NA
69
NewEdge Advisors
Louisiana
– -$45K -1,000 Closed
Balyasny Asset Management
70
Balyasny Asset Management
Illinois
– -$31K -688 Closed
Capstone Investment Advisors
71
Capstone Investment Advisors
New York
– -$28K -628 Closed
TSS
72
Two Sigma Securities
New York
– -$28K -622 Closed
SM
73
Sciencast Management
New Jersey
– -$27K -615 Closed
JG
74
Jefferies Group
New York
– -$25.2K -560 Closed
Bank of America
75
Bank of America
North Carolina
– -$23.1K -498 -100%
1 2
3
4

OTLK Hedge Fund Activity: Q2 2021 in Review

63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2021, worth a combined $50.2M — up 66% from $30.3M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new OTLK positions and 14 closed out — a net gain of 14 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $9.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.87M sold.

  • 63 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2021, up from 49 in Q1 2021.
  • Funds reported $50.2M of Outlook Therapeutics stock for Q2 2021, up 66% quarter-over-quarter.
  • 28 funds opened new Outlook Therapeutics positions in Q2 2021 and 14 closed out, a net change of +14 holders.
  • The largest Outlook Therapeutics buyer in Q2 2021 was BlackRock, an estimated $9.3M added.
  • The largest Outlook Therapeutics seller in Q2 2021 was Renaissance Technologies, an estimated $1.87M sold.

Based on aggregated 13F filings for Q2 2021.